Advertisement

Topics

Insurers are slow to approve pricey new cholesterol drugs

18:03 EDT 4 Oct 2017 | Reuters

(Reuters Health) - During the first year an expensive class of new cholesterol-lowering drugs was on the market, only one in three patients with a prescription actually received the therapy due to lack of insurance approval and high copays, according...

Original Article: Insurers are slow to approve pricey new cholesterol drugs

NEXT ARTICLE

More From BioPortfolio on "Insurers are slow to approve pricey new cholesterol drugs"

Quick Search
Advertisement
 

Relevant Topics

Statins
Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Increased cholesterol levels have been as...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...